Biotech ETF (BBC) Touches Fresh 52-Week High
For investors seeking momentum, Virtus Biotech Clinical Trials ETF BBC is probably on the radar now. The fund just hit a 52-week high and jumped 213.9% from its 52-week low price of $14.16 per share.
But are there more gains in store for this ETF? Let’s take a quick look at the fund and its near-term outlook to get a better sense of where it might head.
BBC in Focus
The fund provides exposure to select clinical trials-stage biotechnology companies. The product charges 79 basis points (bps) in annual fees (See: All Health Care ETFs).
What Led to the Rise?
The BBC ETF recently surged to a 52-week high, primarily driven by a resurgence in "risk-on" sentiment within the biotech sector. This momentum was fueled by a string of positive clinical trial outcomes from core holdings, alongside a significant uptick in M&A activity as Big Pharma seeks to acquire innovative pipelines.
Stabilizing interest rates provided a crucial tailwind for high-growth, pre-revenue companies. Coupled with recent breakthroughs in AI-driven drug discovery, these factors are likely to have created the perfect environment for the fund’s recent peak.
More Gains Ahead?
BBC may continue its strong performance in the near term, with a positive weighted alpha of 170.45 (as per Barchart.com), which suggests a further rally.
Boost Your Portfolio with Our Top ETF Insights
Zacks' exclusive Fund Newsletter delivers actionable information, top news and analysis, as well as top-performing ETFs, straight to your inbox every week.
Don’t miss out on this valuable resource. It’s free!
Get it now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Virtus Biotech Clinical Trials ETF (BBC): ETF Research Reports
This article originally published on Zacks Investment Research (zacks.com).
Source Zacks-com
